Page 2 - Nasdaq Ortx News Today

Cantor Fitzgerald restated their overweight rating on shares of Orchard Therapeutics (NASDAQ:ORTX – Get Rating) in a report released on Monday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Orchard Therapeutics’ FY2023 earnings at ($6.25) EPS. Separately, Oppenheimer increased their price target on Orchard Therapeutics from $5.00 to $37.00 in a research note on Monday, […]

Orchard Therapeutics (NASDAQ:ORTX – Get Rating) released its quarterly earnings data on Monday. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($1.61) by $1.49, MarketWatch Earnings reports. Orchard Therapeutics had a negative net margin of 665.02% and a negative return on equity of 110.80%. The business had revenue of $1.24 […]

Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 129,300 shares, a growth of 46.9% from the March 15th total of 88,000 shares. Currently, 0.8% of the shares of the stock are sold […]

Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 129,300 shares, a growth of 46.9% from the March 15th total of 88,000 shares. Approximately 0.8% of the company’s shares are sold short. Based on an average […]

Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) – Analysts at Cantor Fitzgerald lifted their FY2023 EPS estimates for Orchard Therapeutics in a research report issued on Tuesday, March 28th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($6.25) per share for the year, up from their prior estimate of […]

Orchard Therapeutics (NASDAQ:ORTX – Get Rating) had its target price raised by Cantor Fitzgerald to $15.00 in a research report released on Tuesday morning, The Fly reports. They currently have an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Orchard Therapeutics’ FY2023 earnings at ($6.25) EPS. Separately, Oppenheimer increased their target price […]

OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) ...

All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up Four out of five patients...

Libmeldy® product sales totaled $4.8M in Q3 and $13.0M YTD with market expansion activities continuing in Europe First case of MLD confirmed from...

Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST...